151
Views
10
CrossRef citations to date
0
Altmetric
Original Research

MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 3417-3425 | Published online: 27 Jul 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Qing-Xia Wang, Jiao Xue, Mei-Jie Shi, Yu-Bao Xie, Huan-Ming Xiao, Sheng Li, Ming Lin & Xiao-Ling Chi. (2022) Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B—A Retrospective Cohort Study. Diabetes, Metabolic Syndrome and Obesity 15, pages 2311-2322.
Read now
Xiaoman Chen, Jing Zhou, Lili Wu, Xiang Zhu & Hong Deng. (2022) MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients. Diabetes, Metabolic Syndrome and Obesity 15, pages 673-683.
Read now

Articles from other publishers (8)

Yu-Ming Cheng, Chia-Chi Wang & Jia-Horng Kao. (2022) Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications. Hepatology International 17:2, pages 350-356.
Crossref
Hong Fan, Zhenqiu Liu, Pengyan Zhang, Sheng Wu, Xinyu Han, Yiwen Huang, Yichen Zhu, Xingdong Chen & Tiejun Zhang. (2023) Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis. Hepatology International.
Crossref
Grace En Hui Lim, Ansel Tang, Cheng Han Ng, Yip Han Chin, Wen Hui Lim, Darren Jun Hao Tan, Jie Ning Yong, Jieling Xiao, Chloe Wen-Min Lee, Mark Chan, Nicholas WS. Chew, Eunice Xiang Xuan Tan, Mohammad Shadab Siddiqui, Daniel Huang, Mazen Noureddin, Arun J. Sanyal & Mark D. Muthiah. (2023) An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clinical Gastroenterology and Hepatology 21:3, pages 619-629.e7.
Crossref
Si-Ying Tang, Jian Shiun Tan, Xian-Zheng Pang & Guan-Huei Lee. (2023) Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact. World Journal of Gastroenterology 29:3, pages 549-560.
Crossref
Minghui Zeng, Lin Chen, Yuqin Li, Yuqiang Mi & Liang Xu. (2023) Problems and Challenges Associated with Renaming Non-alcoholic Fatty Liver Disease to Metabolic Associated Fatty Liver Disease. Infectious Diseases & Immunity Publish Ahead of Print.
Crossref
Adrian Kołakowski, Sylwia Dziemitko, Aleksandra Chmielecka, Hubert Żywno, Wiktor Bzdęga, Tomasz Charytoniuk, Adrian Chabowski & Karolina Konstantynowicz-Nowicka. (2022) Molecular Advances in MAFLD—A Link between Sphingolipids and Extracellular Matrix in Development and Progression to Fibrosis. International Journal of Molecular Sciences 23:19, pages 11380.
Crossref
Kai En Chan, Tiffany Jia Ling Koh, Ansel Shao Pin Tang, Jingxuan Quek, Jie Ning Yong, Phoebe Tay, Darren Jun Hao Tan, Wen Hui Lim, Snow Yunni Lin, Daniel Huang, Mark Chan, Chin Meng Khoo, Nicholas W S Chew, Apichat Kaewdech, Naichaya Chamroonkul, Yock Young Dan, Mazen Noureddin, Mark Muthiah, Mohammed Eslam & Cheng Han Ng. (2022) Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals. The Journal of Clinical Endocrinology & Metabolism 107:9, pages 2691-2700.
Crossref
Fajuan Rui, Hongli Yang, Xinyu Hu, Qi Xue, Yayun Xu, Junping Shi & Jie Li. (2022) Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management. Infectious Microbes and Diseases 4:2, pages 49-55.
Crossref